The Atmo Gas Capsule System measures whole gut and regional gut (stomach, small bowel, and colon) transit times. Measurements of gastrointestinal tract transit times are used for evaluating motility disorders such as gastroparesis and slow transit constipation.
The Atmo Gas Capsule System has received U.S. FDA 510(k) clearance and is commercially available in the United States. The Atmo Gas Capsule System is not available in any other market other than as an investigational device when used in approved clinical investigations in accordance with local regulatory requirements.
Image for illustration purposes only. Actual product may differ in appearance.
Gut disorders are common and debilitating
More than 40% of people worldwide are expected to suffer from a functional gut disorder1, affecting quality of life and healthcare use. Functional gut disorders are challenging to manage and a third of patients are expected to remain undiagnosed or suffer from recurrence.
These disorders are characterized by chronic symptoms such as abdominal pain, dysphagia, dyspepsia, diarrhea, constipation and bloating. This condition is caused by disorders of gastrointestinal (GI) function, including dysmotility.
Motility refers to the rate that food contents move through the regions of the gut. Delayed gastric emptying and slow transit constipation are dysmotility conditions. The Atmo Capsule uses data from gas sensors and other onboard sensors to determine its location in the gastrointestinal tract to measure gut motility.
1. Sperber et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study, Gastroenterology, 2021
A simple, easy-to-use solution
The Atmo Gas Capsule is an ingestible capsule that measures gases directly at the source of production in the gastrointestinal tract (GI tract) and transmits the data wirelessly.
The Atmo Gas Capsule System measures whole gut and regional gut (stomach, small bowel, and colon) transit times. Measurements of gastrointestinal tract transit times are used for evaluating motility disorders such as gastroparesis and slow transit constipation.
Transit times are derived from measures of temperature, hydrogen concentration, carbon dioxide concentration, along with indicators of oxygen level, capsule tumble, and antenna reflectance.
The Capsule can electronically report important data from these measures and wirelessly transmits the data which can be uploaded to the Cloud for aggregation, analysis and patient reporting.
How the Atmo Gas Capsule works
Latest News
-
Atmo Biosciences receives US FDA clearance for ingestible gas-sensing capsule.
27 June 2025. Atmo Biosciences is delighted to announce that it has received US Food and Drug Administration (FDA) 510(k) clearance for the Atmo Gas Capsule System, paving the way for its first produc...
-
Atmo Biosciences Strengthens IP Portfolio with Assignment of Patents from RMIT University
April 15, 2025. Atmo Biosciences today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associa...
-
Atmo Biosciences announces publication of pivotal clinical study results supporting initial indication.
March 4, 2025. Today, Atmo Biosciences announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole an...
Media Coverage
BREAKTHROUGH VICTORIA
Founder Interview: Breakthrough Victoria x Atmo Biosciences
19 April 2026
HCP Live
Novel Gas-Sensing Capsule May Provide New Tool for Assessing Motility Disorders
8 November 2024
Medical Advisory Board
Prof. Eamonn Quigley (Chair)
David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology.
Houston Methodist Hospital
Prof. William D. Chey
Chief of Gastroenterology and Hepatology.
University of Michigan
Prof. Satish Rao
Distinguished University Chair in Gastroenterology & Professor of Medicine. Director, Neurogastroenterology/Motility and Digestive Health Clinical Research Center.
Augusta University
Prof. Lin Chang
Professor of Medicine, Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine.
David Geffen School of Medicine at UCLA
Prof. Anthony Lembo
Director of Research for Digestive Disease & Surgery Institute.
Cleveland Clinic
Assoc. Prof. Braden Kuo
Director of Center for Neurointestinal Health at Massachusetts General Hospital and Associate ProfessorHarvard Medical School.
Board of Directors
Malcolm Hebblewhite
President & CEO, Co-Founder
Kate Hill
Chair of the Board & Non-Executive Director
Dr. Chris Roberts AO
Non-Executive Director
Chris Bertrand
Non-Executive Director
Tatsuaki Ohashi
Non-Executive Director
Leadership Team
Dr. Kyle Berean
Head of Clinical Affairs & Co-Founder
Dr. James John
Head of Research and Development/Product Development & Co-Founder
Dr. Carl Runde
Chief Financial Officer & Company Secretary
Dr. Ian Macfarlane
Chief Operating Officer
Matt Reeves
Manufacturing Manager
Professor Kourosh Kalantar-zadeh
Lead Scientific Advisor
